# Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

> **NCT04389073** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 138 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Vinorelbine 40mg
- **BIOLOGICAL:** Toripalimab 240mg
- **BIOLOGICAL:** Bevacizumab 5 mg/kg
- **DRUG:** Cyclophosphamide 50 mg
- **DRUG:** Capecitabine 500Mg Oral Tablet
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04389073
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2022-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04389073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04389073, "Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04389073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*